Benitec Biopharma (BNTC) Insider Kevin Buchi Sells 51,813 Shares
Kevin Buchi sold 51,813 shares of Benitec Biopharma (BNTC) on June 29, 2026, at a spot price of $12.70.
Reviewed by automated data checks against the source filing. How we make and check alerts
Kevin Buchi sold 51,813 shares of Benitec Biopharma Inc. ($BNTC) on June 29, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $BNTC is up 3.9% after 1 week, down 5.1% after 1 month and down 36.1% to date (from the $12.70 close on Jun 29, 2026).
BNTC
Benitec Biopharma Inc.
Key Points
- Kevin Buchi sold 51,813 shares of Benitec Biopharma (BNTC) on June 29, 2026, at a spot price of $12.70.
- Benitec Biopharma is navigating its clinical-stage biotechnology journey, currently valued at about $379.5 million.
- Analysts from Wedbush maintain an 'Outperform' rating on BNTC with a target price of $17.00 as of September 15, 2026.
Get $BNTC trade alerts by text
We text you when insiders, Congress or big funds trade $BNTC. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Benitec Biopharma Inc. alert may contain errors. Disclosures
Kevin Buchi's Insider Sale
Kevin Buchi, a key insider at Benitec Biopharma Inc. (BNTC), sold 51,813 shares on June 29, 2026. At a spot price of $12.70, this sale's value hasn’t been disclosed. It marks a significant transaction in the company's insider trading activity, though further context around the reasoning for the sale isn't provided.
What BNTC Does
Benitec Biopharma is a clinical-stage biotechnology company based in Hayward, California. The firm focuses on developing innovative genetic medicines, utilizing a platform that combines RNA interference with gene therapy. One of their key projects is BB-301, aimed at treating oculopharyngeal muscular dystrophy. The company is currently navigating its way through critical phases in its development pipeline, which contributes to its market cap of approximately $379.5 million.
Analysts Set New Price Targets
On September 15, 2026, Wedbush maintained its 'Outperform' rating for BNTC, increasing the price target to $17.00 from $16.00. Earlier, on July 28, 2026, the firm initiated coverage with a target of $16.00. This positive outlook signals some confidence among analysts regarding the company’s future performance.
How BNTC Stock Has Traded
The stock price of BNTC has fluctuated between $9.85 and $16.76 over the past year. Currently trading at around $12.70, the shares are above their 50-day moving average of $12.39, which might suggest some momentum. Investors often keep a close watch on such averages to gauge potential stock movements.
What's Ahead for BNTC
Investors will be keen on upcoming developments at Benitec Biopharma as the next earnings report is scheduled for November 12, 2026. Insiders’ trading activity, including Buchi’s recent sale, will be closely monitored as a potential indicator of future corporate actions. It's important to remember that this transaction reflects holdings as of June 29, 2026, and may not accurately represent the current situation.
Related Filing Alerts
Source: Kevin Buchi's Form 4 filing on $BNTC (Jun 29, 2026). Find the original filing: BNTC Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts